Agomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial Officer
2024年7月11日 - 8:00PM
ビジネスワイヤ(英語)
Agomab Therapeutics NV (‘Agomab’) today announced that Pierre
Kemula will join the company as Chief Financial Officer (CFO)
effective November 1, 2024, bringing more than 15 years of
experience in global biotech financial leadership. Mr. Kemula joins
Agomab from CureVac N.V. (Nasdaq: CVAC), where he currently serves
as CFO. In this role, Mr. Kemula has led CureVac’s financial and
capital markets activities since 2016, characterized by a
successful listing on Nasdaq and two subsequent follow-on
offerings. Under his leadership, CureVac raised over $1.6 billion
in equity.
Mr. Kemula will succeed Tolga Hassan, who has recently left the
company to explore new opportunities closer to home. Following Mr.
Hassan’s departure, Paul van der Horst, Agomab’s Chief Business
Officer, has been acting as Chief Financial Officer.
“We believe Pierre’s extensive knowledge and experience in the
biotech industry will be highly valuable in driving Agomab through
its next phase of growth. We are looking forward to welcoming
Pierre to our executive team,” said Tim Knotnerus, Chief
Executive Officer of Agomab. “At the same time, I would like to
extend the thanks of the entire management team to Tolga Hassan for
his many contributions to the company’s success over the last
years.”
“Joining Agomab at this important stage in the company's growth
is an incredible opportunity,” said Pierre Kemula. “I am
eager to apply my experience in the global biotech industry and
collaborate with Agomab’s talented team to advance the company’s
novel pipeline of medicines, which have the potential to make a
real difference in patient care.”
Mr. Kemula is a seasoned industry executive with more than 15
years’ experience in financial leadership and management. Before
joining CureVac, Mr. Kemula served as CFO of Pixium Vision, where
he was instrumental in the company's listing on the Euronext in
Paris. His previous roles include Vice President of Corporate
Finance, Treasury, and Financial Markets at Ipsen. Before that, Mr.
Kemula worked with major strategy consulting firms, including
Roland Berger, Bossard Consultants and Gemini Consulting. He holds
a Bachelor of Science in Management Sciences from the London School
of Economics (LSE) in the United Kingdom.
About Agomab
Agomab is focused on achieving disease modification by
modulating fibrosis and regeneration in chronic indications such as
Fibrostenosing Crohn’s Disease and Idiopathic Pulmonary Fibrosis.
We do this by targeting biologically validated pathways - including
Transforming Growth Factor β and Hepatocyte Growth Factor - and by
applying specialized capabilities in organ-restricted small
molecules and high affinity antibodies. With a differentiated
clinical pipeline across several fibrotic disorders, end-to-end
research and development capabilities, a proven BD track-record and
a strong investor base, Agomab is building a leading biopharma
company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240711608759/en/
For Agomab Therapeutics Tim Knotnerus, CEO E-Mail:
tim.knotnerus@agomab.com
Media Requests for Agomab Eva Mulder or Dr. Laura
Mittmann Trophic Communications Phone: +31 6 52 33 15 79 E-Mail:
agomab@trophic.eu